Search by Drug Name or NDC
NDC 68788-8137-02 Butalbital, Acetaminophen, Caffeine 325; 50; 40 mg/1; mg/1; mg/1 Details
Butalbital, Acetaminophen, Caffeine 325; 50; 40 mg/1; mg/1; mg/1
Butalbital, Acetaminophen, Caffeine is a ORAL TABLET in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Preferred Pharmaceuticals Inc.. The primary component is ACETAMINOPHEN; BUTALBITAL; CAFFEINE.
MedlinePlus Drug Summary
This combination of drugs is used to relieve tension headaches. This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.
Related Packages: 68788-8137-02Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Acetaminophen, Butalbital, and Caffeine
Product Information
NDC | 68788-8137 |
---|---|
Product ID | 68788-8137_6beb0447-2292-4320-8e3f-b4fc79873abf |
Associated GPIs | 64991003100310 |
GCN Sequence Number | n/a |
GCN Sequence Number Description | n/a |
HIC3 | n/a |
HIC3 Description | n/a |
GCN | n/a |
HICL Sequence Number | n/a |
HICL Sequence Number Description | n/a |
Brand/Generic | n/a |
Proprietary Name | Butalbital, Acetaminophen, Caffeine |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | Butalbital, Acetaminophen, and Caffeine |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | TABLET |
Route | ORAL |
Active Ingredient Strength | 325; 50; 40 |
Active Ingredient Units | mg/1; mg/1; mg/1 |
Substance Name | ACETAMINOPHEN; BUTALBITAL; CAFFEINE |
Labeler Name | Preferred Pharmaceuticals Inc. |
Pharmaceutical Class | Barbiturate [EPC], Barbiturates [CS], Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE], Methylxanthine [EPC], Xanthines [CS] |
DEA Schedule | CIII |
Marketing Category | ANDA |
Application Number | ANDA209587 |
Listing Certified Through | 2024-12-31 |
Package
NDC 68788-8137-02 (68788813702)
NDC Package Code | 68788-8137-2 |
---|---|
Billing NDC | 68788813702 |
Package | 20 TABLET in 1 BOTTLE (68788-8137-2) |
Marketing Start Date | 2022-02-11 |
NDC Exclude Flag | N |
Pricing Information | N/A |